Who
Munera Maria E. Bedoya-Toro
SVP, Regulatory Affairs
Company insider
Files Form 4 as: SVP, Regulatory Affairs, Dermata Therapeutics; SVP, Regulatory Affairs & QA, Santarus.
In numbers
- Trades disclosed
- 93
- Buys
- 1
- Sells
- 9
- Bought
- $2,540
- Sold
- $1.8M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 Jun 2007
- Last trade
- 17 Feb 2026
- Last filed
- 17 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Feb 2026filed 17 Mar 2026 | DRMA Dermata TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,2701,000 at $1.27 | filing |
| 17 Feb 2026filed 17 Mar 2026 | DRMA Dermata TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,2701,000 at $1.27 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 13 Jan 2025filed 14 Jan 2025 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 4 Jan 2024filed 5 Jan 2024 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 3 Jan 2023filed 5 Jan 2023 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 3 Jan 2022filed 5 Jan 2022 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —61,821 at $0.00 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —400,000 at $0.00 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —100,000 at $0.00 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —357,142 at $0.00 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —280,000 at $0.00 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —100,000 at $0.00 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,878 at $0.00 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata TherapeuticsBiotechnology | SEC FORM 4 Code C | —9,162 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata TherapeuticsBiotechnology | SEC FORM 4 Code C | —19,512 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata TherapeuticsBiotechnology | SEC FORM 4 Code C | —4,878 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata TherapeuticsBiotechnology | SEC FORM 4 Code C | —17,421 | filing |
| 17 Aug 2021filed 17 Aug 2021 | DRMA Dermata TherapeuticsBiotechnology | SEC FORM 4 Code C | —13,658 | filing |
News
No headline names them, or the companies they trade most, lately.